The Manufacturers Life Insurance Company Buys 1,870 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

The Manufacturers Life Insurance Company grew its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 7.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 26,554 shares of the specialty pharmaceutical company’s stock after buying an additional 1,870 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Supernus Pharmaceuticals were worth $710,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Wellington Management Group LLP purchased a new stake in Supernus Pharmaceuticals in the 4th quarter valued at about $1,514,000. Vanguard Group Inc. increased its position in Supernus Pharmaceuticals by 2.3% during the fourth quarter. Vanguard Group Inc. now owns 6,214,731 shares of the specialty pharmaceutical company’s stock worth $179,854,000 after purchasing an additional 142,551 shares during the last quarter. Congress Asset Management Co. MA boosted its stake in Supernus Pharmaceuticals by 12.1% during the first quarter. Congress Asset Management Co. MA now owns 1,032,141 shares of the specialty pharmaceutical company’s stock worth $35,206,000 after buying an additional 111,333 shares during the period. Bridge City Capital LLC boosted its stake in shares of Supernus Pharmaceuticals by 2.5% in the first quarter. Bridge City Capital LLC now owns 80,660 shares of the specialty pharmaceutical company’s stock valued at $2,751,000 after purchasing an additional 1,985 shares during the period. Finally, Hennion & Walsh Asset Management Inc. lifted its stake in Supernus Pharmaceuticals by 71.5% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 39,844 shares of the specialty pharmaceutical company’s stock worth $1,359,000 after acquiring an additional 16,605 shares during the last quarter.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN stock opened at $32.92 on Tuesday. The firm has a market capitalization of $1.81 billion, a PE ratio of 365.78 and a beta of 0.88. The stock has a fifty day moving average of $32.78 and a two-hundred day moving average of $30.25. Supernus Pharmaceuticals, Inc. has a 1 year low of $21.99 and a 1 year high of $35.44.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 EPS for the quarter, missing analysts’ consensus estimates of $0.39 by ($0.03). Supernus Pharmaceuticals had a net margin of 0.83% and a return on equity of 0.56%. The company had revenue of $168.30 million for the quarter, compared to analyst estimates of $148.83 million. During the same period in the prior year, the company posted ($0.02) EPS. The business’s revenue was up 24.1% on a year-over-year basis. Equities research analysts predict that Supernus Pharmaceuticals, Inc. will post 1.53 earnings per share for the current fiscal year.

Analyst Ratings Changes

SUPN has been the topic of several research analyst reports. StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Piper Sandler cut shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $41.00 to $36.00 in a research report on Wednesday, September 11th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.